Risk of fractures associated with treatment for benign prostate hyperplasia in men

Osteoporosis International

Volumn 22, Issue 2, 2011, Pages 731-737

  Vestergaard, P ^a   Rejnmark, L ^a   Mosekilde, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

blockers; 5 reductase inhibitors; Benign prostate hyperplasia; Fracture

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; ANDROSTANOLONE; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; GLUCOCORTICOID; GONADORELIN AGONIST; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT;

AGED; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FALL RISK; FOREARM FRACTURE; FRACTURE; GENERAL PRACTITIONER; HIP FRACTURE; HOSPITAL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESYNCOPE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK FACTOR; SOCIAL ASPECT; SPINE FRACTURE;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FOREARM INJURIES; HIP FRACTURES; HUMANS; MALE; PROSTATIC HYPERPLASIA; RISK FACTORS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 78651519430     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1320-4     Document Type: Article

References (29)

1. W Bushman 2009 Etiology, epidemiology, and natural history of benign prostatic hyperplasia Urol Clin N Am 36 403 415 10.1016/j.ucl.2009.07.003 v
2. SR Tollin HN Rosen K Zurowski B Saltzman AJ Zeind S Berg SL Greenspan 1996 Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia-a Clinical Research Center study J Clin Endocrinol Metab 81 1031 1034 1:CAS:528:DyaK28Xhs1agsL8%3D 8772571 10.1210/jc.81.3.1031
3. B Djavan C Chapple S Milani M Marberger 2004 State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Urol 64 1081 1088 15596173 10.1016/j.urology.2004.07.031
4. SJ Jacobsen TC Cheetham R Haque JM Shi RK Loo 2008 Association between 5-alpha reductase inhibition and risk of hip fracture JAMA 300 1660 1664 1:CAS:528:DC%2BD1cXht1ejsrrF 18840839 10.1001/jama.300.14.1660
5. JK Amory BD Anawalt AM Matsumoto ST Page WJ Bremner C Wang RS Swerdloff RV Clark 2008 The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men J Urol 179 2333 2338 1:CAS:528:DC%2BD1cXntlSmtrc%3D 18423697 10.1016/j.juro.2008.01.145
6. H Matzkin J Chen Y Weisman D Goldray F Pappas N Jaccard Z Braf 1992 Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism Clin Endocrinol (Oxf) 37 432 436 1:STN:280:DyaK3s7jslChug%3D%3D 10.1111/j.1365-2265.1992.tb02355.x
7. AM Matsumoto L Tenover M McClung D Mobley J Geller M Sullivan J Grayhack H Wessells D Kadmon M Flanagan GK Zhang J Schmidt AM Taylor M Lee J Waldstreicher 2002 The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial J Urol 167 2105 2108 11956450 10.1016/S0022-5347(05) 65095-1
8. GL Andriole R Kirby 2003 Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia Eur Urol 44 82 88 1:CAS:528:DC%2BD3sXmt1WntLk%3D 12814679 10.1016/S0302-2838(03)00198-2
9. E Chrischilles L Rubenstein J Chao KJ Kreder D Gilden H Shah 2001 Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study Clin Ther 23 727 743 1:CAS:528:DC%2BD3MXks1Srt7w%3D 11394731 10.1016/S0149-2918(01)80022-9
10. S Dutkiewics 2001 Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia Int Urol Nephrol 32 423 432 1:STN:280: DC%2BD3MrjsFymuw%3D%3D 11583366 10.1023/A:1017595818158
11. GC Hall AD McMahon 2007 Comparative study of modified release alpha-blocker exposure in elderly patients with fractures Pharmacoepidemiol Drug Saf 16 901 907 1:CAS:528:DC%2BD2sXhtVeitrzO 17443863 10.1002/pds.1402
12. J Lee NK Choi SY Jung YJ Kim JM Seong SJ Oh BJ Park 2009 The risk of fracture with taking alpha blockers for treating benign prostatic hyperplasia J Prev Med Public Health 42 165 170 19491559 10.3961/jpmph.2009.42.3.165
13. PC Souverein TP Van Staa ACG Egberts JJMCH De la Rosette C Cooper HGM Leufkens 2003 Use of alpha-blockers and the risk of hip/femur fractures J Intern Med 254 548 554 1:CAS:528:DC%2BD2cXjvVGgsw%3D%3D 14641795 10.1111/j.1365-2796. 2003.01227.x
14. M Wiens M Etminan SS Gill B Takkouche 2006 Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies J Intern Med 260 350 362 1:CAS:528:DC%2BD28Xht1Wntb7P 16961672 10.1111/j.1365-2796.2006.01695.x
15. T Takeuchi T Tsuboi M Arai A Togari 2001 Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells Biochem Pharmacol 61 579 586 1:CAS:528:DC%2BD3MXhsVOhs7s%3D 11239501 10.1016/S0006-2952(00)00591-8
16. P Vestergaard L Rejnmark L Mosekilde 2005 Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark Osteoporos Int 16 134 141 15197546 10.1007/s00198-004-1680-8
17. P Vestergaard C Emborg R Støving C Hagen L Mosekilde K Brixen 2002 Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders- a nationwide register study Int J Eat Disord 32 301 308 12210644 10.1002/eat.10101
18. T Andersen M Madsen J Jørgensen L Mellemkjær J Olsen 1999 The Danish National Hospital Register Dan Med Bull 46 263 268 1:STN:280:DyaK1MzltVyrtw%3D%3D 10421985
19. J Mosbech J Jørgensen M Madsen K Rostgaard K Thornberg T Poulsen 1995 The Danish National Patient Register: evaluation of data quality Ugeskr Laeger 157 3741 3745 1:STN:280:DyaK2Mzlsl2msA%3D%3D 7631448
20. P Vestergaard L Rejnmark L Mosekilde 2004 Fracture risk associated with use of anti-epileptic drugs Epilepsia 45 1330 1337 1:CAS:528:DC%2BD2cXhtVGnsr3M 15509233 10.1111/j.0013-9580.2004.18804.x
21. M Charlson P Pompei K Ales C MacKenzie 1987 A method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chron Dis 40 373 383 1:STN:280:DyaL2s7ms1GnsQ%3D%3D 3558716 10.1016/0021- 9681(87)90171-8
22. P Vestergaard L Rejnmark L Mosekilde 2006 Socioeconomic aspects of fractures within universal public healthcare: a nationwide case-control study from Denmark Scand J Public Health 34 371 377 16861187 10.1080/14034940500441223
23. J Kanis H Johansson O Johnell A Oden C De Laet J Eisman H Pols A Tenenhouse 2005 Alcohol intake as a risk factor for fracture Osteoporos Int 16 737 742 15455194 10.1007/s00198-004-1734-y
24. C Klotzbuecher P Ross P Landsman T Abbott III M Berger 2000 Patients with prior fractures have an increased risk of future fractures: a summary of the litterature and statistical synthesis J Bone Miner Res 15 721 739 1:STN:280:DC%2BD3c3ktFOktA%3D%3D 10780864 10.1359/jbmr.2000.15.4.721
25. P Munk-Jørgensen P Mortensen 1997 The Danish Psychiatric Central Register Dan Med Bull 44 82 84 9062767
26. P Vestergaard L Mosekilde 2002 Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark Am J Epidemiol 156 1 10 12076883 10.1093/aje/kwf007
27. P Strazzullo F Galletti M Cirillo A Siani V Nunziata R Giannattasio M Mancini 1986 Altered extracellular calcium homoeostasis in essential hypertension: a consequence of abnormal cell calcium handling Clin Sci (Lond) 71 239 244 1:CAS:528:DyaL28XltFejsrc%3D
28. L Rejnmark P Vestergaard L Mosekilde 2006 Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study J Hypertens 24 581 589 1:CAS:528:DC%2BD28XhtFyrtrs%3D 16467662 10.1097/01.hjh.0000203845.26690.cb
29. VL Burt JA Cutler M Higgins MJ Horan D Labarthe P Whelton C Brown EJ Roccella 1995 Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991 Hypertension 26 60 69 1:STN:280:DyaK2MzjtFylsg%3D%3D 7607734